Drugs / HEPLISAV
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01999699 | Nov 2013 → Feb 2015 | hepatitis B virus infection | Dynavax Technologies Corporation | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00511095 | Jun → Oct 2007 | hepatitis B virus infection | Dynavax Technologies Corporation | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT02117934 | Apr 2014 → Oct 2015 | — | Dynavax Technologies Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01195246 | Dec 2010 → Feb 2012 | end stage renal failure | Dynavax Technologies Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01005407 | Feb 2010 → Jan 2011 | — | Dynavax Technologies Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00435812 | Dec 2006 → Feb 2008 | hepatitis B virus infection | Dynavax Technologies Corporation | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HEPLISAV | “new investigational hepatitis B virus (HBV) vaccine, HEPLISAV™” NCT00511095 ↗ |
| Known as | HBsAg-1018 | “Phase 3 observer-blinded, randomized (2:1 HBsAg-1018 [HEPLISAV-B™]:HBsAg-Eng [Engerix-B®]), active-controlled trial” PMID 29289383 ↗ Dec 2017 |
| Modality | Vaccine | “new investigational hepatitis B virus vaccine, HEPLISAV™” NCT00435812 ↗ |
| Route | Intramuscular | “Intramuscular (IM) injections on Week 0, Week 4; placebo (saline) injection at Week 24” NCT00435812 ↗ |